Code Waechter LLC Grows Stock Holdings in Sanofi $SNY

Code Waechter LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 27.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,182 shares of the company’s stock after buying an additional 3,277 shares during the period. Code Waechter LLC’s holdings in Sanofi were worth $733,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Axxcess Wealth Management LLC grew its position in Sanofi by 130.5% in the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company’s stock worth $568,000 after acquiring an additional 5,794 shares in the last quarter. Ballentine Partners LLC grew its position in Sanofi by 68.7% in the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company’s stock worth $1,445,000 after acquiring an additional 10,617 shares in the last quarter. Voya Investment Management LLC grew its position in Sanofi by 11.6% in the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock worth $11,460,000 after acquiring an additional 21,540 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new position in Sanofi in the first quarter worth $332,000. Finally, Ascent Group LLC purchased a new position in Sanofi in the first quarter worth $426,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Finally, Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Stock Performance

NASDAQ SNY opened at $50.05 on Tuesday. The company has a 50-day simple moving average of $48.69 and a two-hundred day simple moving average of $49.53. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The firm has a market cap of $122.90 billion, a price-to-earnings ratio of 11.72, a PEG ratio of 1.38 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $14.53 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same period in the prior year, the business posted $2.25 earnings per share. The company’s revenue was down 7.5% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.